PracticeUpdate Conference Series ASH 2018

© ASH/Rodney White 2018

Contents

ASH 2018 • 1–4 December 2018 • San Diego, California, USA BY THE PRACTICEUPDATE EDITORIAL TEAM

6

11

18

4 Shorter Course of CHOP + Rituximab 5 Expedited Genetic Screening Feasible for Detecting Subtypes of Acute Myeloid Leukemia 6 Combining CAR T-Cell Therapy With PD-1 Checkpoint Inhibitors Could Improve Response Persistence 7 L-Glutamine Benefits Consistent Regardless of History of Sickle Cell Disease Crises 8 Microbiome Injury Prior to Hematopoietic Stem Cell Transplantation Predicts Survival Noninferior to Standard of Care in Younger Patients With DLBCL

10 Hydroxyurea a Feasible Sickle Cell Therapy in Sub-Saharan Africa 11 First Transplant Following CAR T-Cell Therapy Boosts Leukemia-Free Survival in ALL 12 Doctors Underestimate the Impact of Fatigue Related to Immune Thrombocytopenia 13 Smoking Linked With Poorer Outcomes In Newly Diagnosed ALL Treated With TKIs 14 Older Patients With CLL See Better Outcomes With Ibrutinib Than Chemoimmunotherapy

15 Luspatercept Reduces Need for Blood Transfusions Among Patients With Beta Thalassemia 16 Direct Oral Anticoagulants Safely Reduce Clotting Risk In Outpatient Cancer Setting 16 Ibrutinib-Based Therapy Beats Standard of Care as First-Line in Young Patients With CLL 18 Daratumumab Improves Outcomes in Fragile Patients With Multiple Myeloma 19 Emapalumab Safe and Effective in Pediatric Patients With Primary HLH 20 Tisagenlecleucel Effectively Treats ALL in Update of ELIANA Trial

The production and distribution of this publication is sponsored by Gilead Sciences. The provision of this information is not intended to advocate any use not covered by the Product Information. Please check that the product is approved for use and always consult the Product Information before prescribing.

1

ASH 2018 • PRACTICEUPDATE CONFERENCE SERIES